EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns

Leila Abassi, Federico Bertoglio iD, Željka Mačak Šafranko, Thomas Schirrmann, Marina Greweling-Pils, Oliver Seifert iD, Fawad Khan, Maeva Katzmarzyk, Henning Jacobsen, Natascha Gödecke, Philip Alexander Heine, André Frenzel und 8 weitere

Viruses · 2023

DOI: 10.3390/v15112153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Leila Abassi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Viral Immunology, Helmholtz Centre for Infection Research, Inhoffenstr. 7, 38124 Braunschweig, Germany. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Bispecific, Vaccines, Hepatitis D. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Niedersächsisches Ministerium für Wissenschaft und Kultur, Helmholtz Association of German Research Centres, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As of now, the COVID-19 pandemic has spread to over 770 million confirmed cases and caused approximately 7 million deaths. While several vaccines and monoclonal antibodies (mAb) have been developed and deployed, natural selection against immune recognition of viral antigens by antibodies has fueled the evolution of new emerging variants and limited the immune protection by vaccines and mAb. To optimize the efficiency of mAb, it is imperative to understand how they neutralize the variants of concern (VoCs) and to investigate the mutations responsible for immune escape. In this study, we show the in vitro neutralizing effects of a previously described monoclonal antibody (STE90-C11) against the SARS-CoV-2 Delta variant (B.1.617.2) and its in vivo effects in therapeutic and prophylactic settings. We also show that the Omicron variant avoids recognition by this mAb. To define which mutations are responsible for the escape in the Omicron variant, we used a library of pseudovirus mutants carrying each of the mutations present in the Omicron VoC individually. We show that either 501Y or 417K point mutations were sufficient for the escape of Omicron recognition by STE90-C11. To test how escape mutations act against a combination of antibodies, we tested the same library against bispecific antibodies, recognizing two discrete regions of the spike antigen. While Omicron escaped the control by the bispecific antibodies, the same antibodies controlled all mutants with individual mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antibodies, BispecificVaccinesHepatitis DHumansAntibodies, NeutralizingSARS-CoV-2PandemicsAntibodies, MonoclonalAntibodies, ViralSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

Delta variantSARS-CoV-2bispecific antibodiesintranasal administrationintravenous administrationmice experimentsmonoclonal antibodypseudovirus assaysingle mutations

Substanzen

Antibodies, NeutralizingAntibodies, BispecificAntibodies, MonoclonalVaccinesAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Viral Immunology, Helmholtz Centre for Infection Research, Inhoffenstr. 7, 38124 Braunschweig, Germany.
  • Institut für Biochemie, Biotechnologie und Bioinformatik, Technische Universität Braunschweig, Spielmannstr. 7, 38106 Braunschweig, Germany.
  • Research Department, University Hospital for Infectious Diseases "Dr. Fran Mihaljević", 10000 Zagreb, Croatia.
  • YUMAB GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.
  • Core Facility of Comparative Medicine, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany.
  • Institute of Cell Biology and Immunology, University of Stuttgart, 70174 Stuttgart, Germany.

ORCID-Profile: Federico Bertoglio, Oliver Seifert, Ivan-Christian Kurolt, Maren Schubert, Luka Čičin-Šain

Förderung

  • Niedersächsisches Ministerium für Wissenschaft und Kultur
  • Helmholtz Association of German Research Centres
  • European Union
  • Ministry of Science and Culture of Lower Saxony
  • Helmholtz Association
  • MCMVaccine

Zitieren

APA

Abassi, L., Bertoglio, F., Mačak Šafranko, Ž., Schirrmann, T., Greweling-Pils, M., Seifert, O., Khan, F., Katzmarzyk, M., Jacobsen, H., Gödecke, N., Heine, P. A., Frenzel, A., Nowack, H., Dübel, S., Kurolt, I. C., Kontermann, R. E., Markotić, A., Schubert, M., Hust, M., & Čičin-Šain, L. (2023). Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. Viruses. https://doi.org/10.3390/v15112153

Vancouver

Abassi L, Bertoglio F, Mačak Šafranko Ž, Schirrmann T, Greweling-Pils M, Seifert O, et al. Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. Viruses. 2023. doi:10.3390/v15112153

BibTeX
@article{Abassi2023,
  author = {Abassi, Leila and Bertoglio, Federico and Mačak Šafranko, Željka and Schirrmann, Thomas and Greweling-Pils, Marina and Seifert, Oliver and Khan, Fawad and Katzmarzyk, Maeva and Jacobsen, Henning and Gödecke, Natascha and Heine, Philip Alexander and Frenzel, André and Nowack, Helena and Dübel, Stefan and Kurolt, Ivan-Christian and Kontermann, Roland E and Markotić, Alemka and Schubert, Maren and Hust, Michael and Čičin-Šain, Luka},
  title = {Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15112153}
}
Kostenlos starten →